Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ann Davis

Cardiovascular Disease Naperville, IL Medical Doctor

NPI 1528012846 CMS profile 296087

801 S Washington St Fl 4, Naperville, IL 60540

Open in the dashboard

General payments

$27,179

783 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ann Davis of Naperville, IL is reported in the CMS Open Payments database as having received $27,179 across 783 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,596 82
2024 General $3,883 82
2023 General $3,705 122
2022 General $3,307 118
2021 General $2,388 119
2020 General $1,699 85
2019 General $8,603 175

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ann Davis
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ann Davis were reported at $3,596. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ann Davis Cardiovascular Disease median Middle half National median
2019 $8,603 $450 $127–$1,392 $163
2020 $1,699 $242 $77–$751 $114
2021 $2,388 $335 $101–$1,037 $132
2022 $3,307 $395 $121–$1,211 $149
2023 $3,705 $443 $136–$1,283 $160
2024 $3,883 $450 $136–$1,323 $164
2025 $3,596 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $9,483 116 payments
  2. AstraZeneca Pharmaceuticals LP $2,524 58 payments
  3. E.R. Squibb & Sons, L.L.C. $2,446 88 payments
  4. Novartis Pharmaceuticals Corporation $1,529 106 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,363 24 payments
  6. Pfizer Inc. $1,169 45 payments
  7. Kowa Pharmaceuticals America, Inc. $1,011 100 payments
  8. Janssen Pharmaceuticals, Inc $874 45 payments
  9. Amarin Pharma Inc. $795 50 payments
  10. Esperion Therapeutics, Inc. $624 36 payments
  11. Other $5,361 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,513 773 payments
  2. Consulting Fee $3,600 1 payment
  3. Travel and Lodging $1,020 4 payments
  4. Education $46 5 payments
Products named General payments · program years 2019–2025
  1. Repatha $9,147 109 payments
  2. ELIQUIS $1,301 62 payments
  3. FARXIGA $1,049 24 payments
  4. CAMZYOS $1,023 24 payments
  5. Livalo $994 99 payments
  6. XARELTO $874 45 payments
  7. JARDIANCE Diabetes $689 14 payments
  8. LEQVIO $688 40 payments
  9. JARDIANCE Diabetes $674 10 payments
  10. NEXLETOL $624 36 payments
  11. Other $11,905 433 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

4,482

Median for Cardiology: 2,533

Drug cost

$389,693

Median for Cardiology: $485,213

Branded share of claims

12.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 105 $153,231
Repatha Sureclick Evolocumab Brand 65 $61,063
Xarelto Rivaroxaban Brand 46 $55,060
Jardiance Empagliflozin Brand 30 $45,265
Repatha Syringe Evolocumab Brand 11 $11,766
Praluent Pen Alirocumab Brand 14 $10,423
Metoprolol Succinate Generic 545 $6,691
Atorvastatin Calcium Generic 518 $5,022
Vascepa Icosapent Ethyl Brand 12 $4,937
Ezetimibe Generic 265 $4,828

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$179,227

Medicare's payments for the services billed

Medicare patients

644

Average age 75

Services billed

2,487

442 women, 202 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 52%
Arthritis 51%
Diabetes 32%
Chronic kidney disease 28%
Atrial fibrillation 24%
Heart failure 21%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $1,163
$1,163 76 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $301
$301 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $260
$260 30 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $245
$245 — —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $234
$234 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

783 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record